SHR-1819
As of the edition of 20 October 2026, SHR-1819 is a drug known only by a code name: in active development; acts on IL4R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Code name only
- Registered trials
- 12, 0 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Inherited and neonatal; Lungs and airways; Ear, nose and throat
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL4R | Interleukin-4 receptor subunit alpha | P24394 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 5 | 4 | 1 | 0 |
| Phase 3 | 4 | 1 | 3 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Atridia | Lead sponsor of trials | 2020 to now |
| Hengrui Pharmaceutical | Lead sponsor of trials | 2021 to now |
| Guangdong Hengrui Pharmaceutical | Lead sponsor of trials | 2024 to now |